Method and Apparatus for Disease Diagnosis and Screening Using Extremely Low Frequency Electromagnetic Fields

• US 20100049078A1
• Filed: 08/13/2009
• Published: 02/25/2010
• Est. Priority Date: 08/22/2008
• Status: Active Grant

• Current Assignee: Mark L. Faupel
• Original Assignee: Mark L. Faupel
• Inventors: FAUPEL, Mark L.
• Granted Patent: US 8,712,515 B2
• Time in Patent Office: Days
• US Class Current: 600/547
• CPC Class Codes: A61B 2562/0215 Silver or silver chloride containing
• CPC Class Codes: A61B 2562/046 in a matrix array
• CPC Class Codes: A61B 5/24 Detecting, measuring or recording bioelectric or biomagnetic signals of the body or parts thereof
• CPC Class Codes: A61B 5/7264 Classification of physiological signals or data, e.g. using neural networks, statistical classifiers, expert systems or fuzzy systems neural networks per se G06N3/00; expert systems per se G06N5/00

Abstract

Novel methods and apparatus for diagnosing or screening disease states in living organisms by the measurement and analysis of extremely low frequency electromagnetic fields, particularly extremely low frequency alternating current. The measurement of such fields is performed at a single point or at several test points on or in the body and compared to one or more reference. Information in the time-varying electromagnetic field is collected, then processed by diagnostic or screening algorithms to provide information about the disease state of the tissue being assessed.

Claims

1. A method of screening for or diagnosing a disease condition in a test subject comprising:

obtaining electromagnetic frequency signals between a test site and a reference site via at least one sensor electrode and at least one reference electrode;

band pass filtering the signals obtained by the sensor electrode to yield sensor ELFAC signals;

bandpass filtering the signals obtained by the reference electrode to yield reference ELFAC signals;

determining likelihood of disease based upon said ELFAC signals.

2. The method of claim 1, wherein said ELFAC signals are sent to a processing unit for use in the determining step, and wherein said processing unit outputs the determined result to a display device.

3. The method of claim 1, wherein said determining step comprises comparing one or more ELFAC field waveform measurement selected from periodicity, frequency, peaks, troughs, slopes, fractal dimensions, and chaos.

4. The method of claim 3, wherein said comparing step further comprises:

correlating similar sensor and reference data with a low risk of disease state; and

correlating dissimilar sensor and reference data with a higher risk of disease state.

5. The method of claim 1, wherein the reference electrode is placed on the test subject at a location complimentary or symmetrical to said test site.

6. The method of claim 1 wherein the reference electrode contacts a reference standard solution.

7. The method of claim 1 wherein noise-minimized ELFAC data is used for said determining step, wherein noise-minimized status is established by

continuously measuring ELFAC waveforms at said sensor electrode and said reference electrode during an equilibration period, wherein said equilibration period ending, and noise-minimized data being achieved when substantially all of the measured ELFAC fields reach equilibrium.

8. The method of claim 7 whereby the comparing step is not performed unless and until noise-minimized ELFAC data has been achieved.

9. The method of claim 7 wherein noise-minimized ELFAC data are integrated with user input biological subject variables and compared using pattern recognition techniques, and a probability of the presence of a disease state is determined as a result of the pattern recognition.

10. The method of claim 9, wherein said biological subject variables are selected from age of the subject, menopausal stage, day in the menstrual cycle, palpability of a suspicious lesion, size of a suspicious lesion, dimensions of a suspicious lesion, and combinations thereof.

11. The method of claim 9 in which the biological subject variable is the menopausal stage of the subject from which the pattern recognition technique and waveform values to be employed for a given subject are determined.

12. The method of claim 9 in which the biological subject variable is the day in the menstrual cycle of the subject from which the pattern recognition technique and waveform values to be employed for a given subject are determined.

13. The method of claim 9 in which the biological subject variable the palpability of a suspicious lesion from which the pattern recognition technique and waveform values to be employed for a given subject is determined.

14. The method of claim 9 in which the size or dimensions of a suspicious lesion determines the pattern recognition technique and waveform values to be employed for a given subject.

15. The method of claim 9 in which the age of the subject determines the pattern recognition technique and waveform values to be employed for a given subject.

16. The method of claim 9 which includes detecting and analyzing ELFAC waveform data in said subject between a least one location remote from the test site and said reference site and comparing the relationship between the remote measurement site ELFAC data and ELFAC data measured from at least one sensor electrode located at the test site, which includes determining the presence or absence of a disease state by comparison of said ELFAC data.

17. The method of claim 16 by wherein said sensing electrode(s) at remote location on the subject is spaced away from the test site.

18. The method of claim 1 whereby electropotential measurements are taken sequentially from one or more locations on or in the body of a test subject.

19. The method of claim 1 whereby electropotential measurements are taken simultaneously or concurrently from one or more locations on or in the body of a subject human or animal.

20. The method of claim 7, further comprising

grouping ELFAC signals for each possible sensor electrode/reference electrode combination;

calculating a measure of central tendency of said signals taken from noise-minimized ELFAC measurements;

comparing said measures of central tendency for the purpose of disease diagnosis and screening.

21. The method of claim 1, further comprising removing of the stratum corneum at least one of said test site and said reference site by concentrating a laser light on a dye layer placed on the skin surface to facilitate contact of the electrode.

22. An apparatus for disease detection or diagnosis at a test site on or in a test subject, said apparatus comprising:

at least one sensor electrode designed for contact with the test site;

at least one reference electrode for contact with a reference site;

a bandpass filter allowing passage of extremely low frequency alternating currents (ELFACs) within the frequency range 0.001 Hz to 0.1 Hz;

a processing means, configured to collect, analyze and store data obtained from the electrodes;

wherein said sensor electrode, reference electrode are operatively coupled to the processing means via the band pass filter.

23. The apparatus of claim 22 whereby the reference electrodes are of the same type as the sensing electrodes and placed at a location away from the test site on or in the test subject.

24. The apparatus of claim 22 whereby the reference electrodes are in contact with a solution of normal saline or other artificial reference material.

25. The apparatus of claim 22, further comprising

analog-to-digital converter component connected to receive each ELFAC signal from each said sensor electrode and said reference electrode and

wherein said processing means is connected to receive each said digital signal, said processing means operating to compare said digital ELFAC signals to yield a disease diagnosis or probability indicator.

26. The apparatus of claim 22, wherein at least one of said sensor electrodes or said reference electrodes comprises

an adhesive outer portion which affixes the electrode to the surface of the test or reference site,

an inner portion further comprising one or more micro- or mini-electrodes of a length capable of penetrating the corneal layer of the skin or outer layer of the organ system at the test site, and

wherein each micro- or mini-electrode is operatively coupled to the processing means.

27. The apparatus of claim 22, wherein said processing means comprises an equilibration module wherein each ELFAC signal is analyzed for equilibrium, such that only once equilibrium is reached, doe the process perform further analyses.

28. The apparatus of claim 22, wherein said processing means comprises a pattern recognition module, wherein the sensor ELFAC data is compared to the reference ELFAC data, and correlated to the likelihood of a disease state being present.